Since then, there have been several immunotherapy drugs and immunotherapy technologies developed every year. Two such drugs are nivolumab and pembrolizumab. Both are FDA approved for the treatment of ...

Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.

CHICAGO — An alternative dosing strategy of pembrolizumab and nivolumab may substantially reduce pharmaceutical costs without compromising efficacy in treating various cancers, according to ...

References: van Rijssen L, Nagtegaal IEC, Ploos van Amstel FK, et al. Safety of accelerated infusion of nivolumab and pembrolizumab. Eur J Cancer.Published online March 21, 2025. doi:10.1016/j ...

More patients in the nivolumab-ipilimumab group than the pembrolizumab group experienced grade 3 or higher non-hematological adverse events (60% vs 41%), and the dual immunotherapy group had more ...

The pivotal CheckMate 067 trial, which evaluated the combination of nivolumab, an anti–PD-1 agent like pembrolizumab, and ipilimumab against either drug alone in patients with melanoma, reported ...

The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the ...